CJC-1295 Research
Long-Acting GHRH Analog
growth hormone signaling
Immune Support, Training and Energy
Educational information only. Investigational uses may lack FDA approval. Not medical advice or a treatment plan.
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) engineered for an extended pharmacokinetic profile. Through a drug affinity complex (DAC) technology that enables albumin binding, it achieves a prolonged half-life compared to native GHRH. It is studied for its role in sustained growth hormone axis stimulation and downstream signaling pathway research.
Research areas
GHRH Receptor Signaling
Research examines CJC-1295's agonism at pituitary GHRH receptors, investigating its downstream activation of adenylyl cyclase signaling, cAMP production, and somatotroph stimulation pathway research.
Pharmacokinetic & Half-Life Research
Studies investigate the DAC (drug affinity complex) mechanism that enables albumin binding, exploring how extended receptor exposure affects GH pulse dynamics compared to native GHRH signaling.
Growth Hormone Axis Stimulation
Researchers study its effects on sustained GH secretion signaling over multi-day dosing intervals, exploring pituitary somatotroph responsiveness and GH axis feedback pathway research.
IGF-1 Downstream Pathway Research
Studies examine its downstream effects on hepatic IGF-1 production, IGF-binding protein signaling, and tissue-level anabolic pathway research associated with sustained GHRH receptor activation.
Investigational compound. Not FDA-approved. Often studied in combination with Ipamorelin. Not medical advice.
Have questions about CJC-1295?
Request a free consultation to ask questions and learn more about this research area.
Request a free consultation